TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Read More

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT

Read More

As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent Pharmaceuticals

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman Mehta leads the firm with an ambitious future vision. He spearheaded a significant acquisition and focuses on weightloss drugs. Mehta emphasizes making the right strategic decisions for success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aa2ZNnG
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6yfHqpD
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xmdxj2f
via IFTTT

Read More

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

The FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient good manufacturing practices. These deficiencies posed a significant risk to public health and safety. The company failed to ensure product safety, quality, and traceability. All operations must cease until compliance is fully established.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SpORKHG
via IFTTT

Read More

Gland Pharma gets USFDA nod for generic sugammadex injection

Gland Pharma secured USFDA approval for its sugammadex injection generic version. This drug reverses muscle relaxant effects used during surgical procedures. The approval covers two specific strengths of the single-dose vial product. This new generic is bioequivalent to Merck's BRIDION injection. The product had significant US sales in the past year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NQSndia
via IFTTT

Read More